Illumina, Inc. vs KraneShares Hang Seng TECH Index ETF — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while KraneShares Hang Seng TECH Index ETF trades at $13.5. The key difference: Illumina, Inc. is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | KTEC | |
|---|---|---|
Market Cap | $28.96B | — |
Sector | Health | Sector/Thematic |
52-Week High | $205.10 | $19.51 |
52-Week Low | $91.00 | $12.00 |
Enterprise Value | $30.32B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
KTEC trades at $13.78, up 1.47% today, with a bullish technical signal driven by moving averages. Support and resistance cluster at $14, indicating a critical price zone. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights China's AI competition as a potential catalyst for tech ETFs like KTEC.
The stock's outlook hinges on AI sector momentum, but risks include reliance on thematic trends and lack of disclosed financials. Upside depends on broader tech ETF inflows, while volatility from geopolitical or market shifts poses a near-term challenge.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →